About
Drug discovery for complex peptides/SMs/mAbs; display tech, HTS, DMPK, in vivo, functional genomics
Areas of Focus
Categories
Contract ResearchContract ResearchContract ResearchContract ResearchContract ResearchContract ResearchContract Research
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
0
As Collaborator
5
Total Enrollment
178
By Phase
PHASE1/PHASE2: 4
By Status
RECRUITING: 3NOT_YET_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT05745714Collaborator
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Recruiting
26 participants
Started: Oct 1, 2025 · Completed: Feb 2, 2032
NCT05751044Collaborator
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Recruiting
26 participants
Started: Oct 1, 2025 · Completed: Feb 1, 2032
NCT06154590Collaborator
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
N/ANot yet recruiting
100 participants
Started: Jul 31, 2024 · Completed: Sep 30, 2026
NCT05658640Collaborator
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Recruiting
26 participants
Started: Nov 14, 2023 · Completed: Apr 1, 2029
NCT05740449Collaborator
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Withdrawn
Started: Oct 1, 2023 · Completed: Oct 1, 2029
Locations (1)
Headquarters
Pomezia, Italy
Map
Loading map...